Analyst Keay Nakae from Chardan Capital maintained a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price target at $55.00. Keay Nakae has given his Buy
Analyst Keay Nakae from Chardan Capital maintained a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price target at $55.00. Keay Nakae has given his Buy
Silence Therapeutics (SLN) has released an update. Silence Therapeutics has unveiled promising Phase 2 trial results for its siRNA treatment, zerlasiran, showing significant reductions in lipoprotein(a) levels in patients with
Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA, or siRNA, in atherosclerotic cardiovascular disease, or ASCVD, patients with high lipoprotein(a)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a price target of $75.00. Patrick Trucchio has
Analyst Michael Ulz of Morgan Stanley reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), retaining the price target of $49.00. Michael Ulz has given his Buy rating